Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 21 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Atezolizumab in combination with bevacizumab for untreated unresectable or advanced hepatocellular carcinoma	Atezolizumab (Tecentriq; MPDL3280A) , Bevacizumab (Avastin; R 435; RG 405; RG 435)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2019	View \| Download
Atezolizumab with bevacizumab for patients with resected or ablated hepatocellular carcinoma who are at high risk for disease recurrence	Atezolizumab (Tecentriq; MPDL3280A) , Bevacizumab (Avastin; R 435; RG 405; RG 435)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2022	View \| Download
Cabozantinib for Hepatocellular Carcinoma	Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2017	View \| Download
Cabozantinib in combination with atezolizumab for advanced hepatocellular carcinoma –first line	Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2021	View \| Download
Durvalumab adjuvant therapy for treating hepatocellular carcinoma at high risk of recurrence after curative treatment	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2022	View \| Download
Durvalumab and bevacizumab in addition to transarterial chemoembolisation for locoregional hepatocellular carcinoma	Bevacizumab (Avastin; R 435; RG 405; RG 435) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Transarterial Chemoembolisation (TACE)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2021	View \| Download
Durvalumab for previously untreated,hepatocellular carcinoma	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2021	View \| Download
Durvalumab in combination with tremelimumab for unresectable hepatocellular carcinoma – first line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2019	View \| Download
Durvalumab with bevacizumab adjuvant therapy for treating newly diagnosed hepatocellular carcinoma at high risk of recurrence after curative therapy	Bevacizumab (Avastin; R 435; RG 405; RG 435) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2022	View \| Download
Durvalumab with transarterial chemoembolisation for hepatocellular carcinoma	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Transarterial Chemoembolisation (TACE)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2022	View \| Download